Valtrex and Abreva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Valtrex (valacyclovir hydrochloride) and Abreva (docosanol). Common drug interactions include drug ineffective among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Valtrex and Abreva. It is created by eHealthMe based on reports of 52 people who take the same drugs from the FDA, and is updated regularly.

What is Valtrex?

Valtrex has active ingredients of valacyclovir hydrochloride. It is often used in genital herpes. eHealthMe is studying from 40,000 Valtrex users. Check the latest studies of Valtrex.

What is Abreva?

Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 17,071 Abreva users. Check the latest studies of Abreva.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

52 people who take Valtrex and Abreva together, and have interactions are studied.

What are the common drug interactions of Valtrex and Abreva, by gender? *:

female:

Drug ineffective
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Faecal volume increased
Fatigue (feeling of tiredness)
Haematochezia (passage of stools containing blood)
Haemorrhoids (a swollen vein or group of veins in the region of the anus)
Lip swelling
Mucous stools (mucous with stool)
Anxiety
Application site dryness

male:

Drug ineffective

What are the common drug interactions of Valtrex and Abreva, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Application site dryness
Drug ineffective
Oedema (fluid collection in tissue)

30-39:

Drug ineffective
Abdominal discomfort
Anxiety
Application site erythema (redness of the skin at application site)
Chest pain
Dysuria (painful or difficult urination)
Initial insomnia (feeling of inadequate or poor-quality sleep)
Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
Muscle spasms (muscle contraction)

40-49:

Drug ineffective
Hypersensitivity
Application site irritation
Drug hypersensitivity
Drug intolerance (drug sensitivity)
Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
Hallucination, auditory (perceiving sounds without auditory stimulus)
Impaired work ability
Lip swelling
Oral herpes (viral infection of mouth)

50-59:

Diarrhoea
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Dyspnoea (difficult or laboured respiration)
Faecal volume increased
Fatigue (feeling of tiredness)
Haematochezia (passage of stools containing blood)
Haemorrhoids (a swollen vein or group of veins in the region of the anus)
Mucous stools (mucous with stool)
Dizziness
Drug ineffective

60+:

Drug ineffective
Helicobacter infection (helicobacter pylori (h. pylori) infects stomach)
Iron deficiency
Oral herpes (viral infection of mouth)
Sinus headache (headache caused by sinus infections)

What are the existing conditions these people have? *

Oral Herpes (viral infection of mouth): 18 people, 34.62%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 9.62%
Stress And Anxiety: 4 people, 7.69%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Valtrex and Abreva?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously